Alnylam Pharmaceuticals
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.About ALNY
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference.
ALNY Key Statistics
Stock Snapshot
The current Alnylam Pharmaceuticals(ALNY) stock price is $318.11, with a market capitalization of 42.51B. The stock trades at a price-to-earnings (P/E) ratio of 137.65.
On 2026-03-07, Alnylam Pharmaceuticals(ALNY) stock moved within a range of $312.09 to $321.16. With shares now at $318.11, the stock is trading +1.9% above its intraday low and -0.9% below the session's peak.
Trading activity shows a volume of 996.49K, compared to an average daily volume of 1.02M.
Over the past 52 weeks, Alnylam Pharmaceuticals(ALNY) stock has traded between a high of $495.55 and a low of $205.87.
Over the past 52 weeks, Alnylam Pharmaceuticals(ALNY) stock has traded between a high of $495.55 and a low of $205.87.
ALNY News
Alnylam Pharmaceuticals (ALNY) just agreed to a research collaboration with Tenaya Therapeutics that centers on discovering up to 15 human genetic targets for p...
Wondering whether Alnylam Pharmaceuticals at around US$320 a share still makes sense for your portfolio, or if the value case has shifted? This article will wal...
Tenaya Therapeutics ( (TNYA) ) just unveiled an update. On March 4, 2026, Tenaya Therapeutics entered into a collaboration agreement with Alnylam Pharmaceutica...
Analyst ratings
76%
of 29 ratingsMore ALNY News
Tenaya Therapeutics (TNYA) added ~10% in the premarket on Thursday after the company signed a research collaboration with Alnylam Pharmaceuticals (ALNY) to disc...
Tenaya Therapeutics (TNYA) announced a research collaboration agreement with Alnylam Pharmaceuticals (ALNY) to discover novel human genetic targets for the pote...
(RTTNews) - Tenaya Therapeutics (TNYA) announced a research collaboration agreement with Alnylam Pharmaceuticals (ALNY), to discover human genetic targets for t...
Alnylam Pharmaceuticals (NasdaqGS:ALNY) has completed the KARDIA-3 Phase 2 trial of zilebesiran in patients with difficult to treat hypertension. The company a...
In late February 2026, Alnylam Pharmaceuticals highlighted strong momentum for its RNAi franchise, including positive Phase 3 data and a favorable Canadian reim...
Alnylam Pharmaceuticals (ALNY) announced an update on their ongoing clinical study. KARDIA-3 tests Alnylam’s drug zilebesiran as add-on therapy for adults with...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.